Market openADR
BeiGene/$BGNE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BeiGene
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Ticker
$BGNE
Sector
Trading on
Industry
Biotechnology
Headquarters
Camana Bay, Cayman Islands
Employees
10,600
Website
BeiGene Metrics
BasicAdvanced
$20B
Market cap
-
P/E ratio
-$7.87
EPS
0.60
Beta
-
Dividend rate
Price and volume
Market cap
$20B
Beta
0.6
52-week high
$243.06
52-week low
$126.97
Average daily volume
414K
Financial strength
Current ratio
1.938
Quick ratio
1.645
Long term debt to equity
6.391
Total debt to equity
30.545
Interest coverage (TTM)
-57.74%
Management effectiveness
Return on assets (TTM)
-9.58%
Return on equity (TTM)
-23.22%
Valuation
Price to revenue (TTM)
5.986
Price to book
0.81
Price to tangible book (TTM)
0.84
Price to free cash flow (TTM)
-16.365
Growth
Revenue change (TTM)
50.22%
Earnings per share change (TTM)
-16.40%
3-year revenue growth (CAGR)
46.66%
3-year earnings per share growth (CAGR)
-17.55%
What the Analysts think about BeiGene
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BeiGene stock.
BeiGene Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BeiGene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BeiGene News
AllArticlesVideos
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Business Wire·6 days ago
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Business Wire·1 week ago
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BeiGene stock?
BeiGene (BGNE) has a market cap of $20B as of January 02, 2025.
What is the P/E ratio for BeiGene stock?
The price to earnings (P/E) ratio for BeiGene (BGNE) stock is 0 as of January 02, 2025.
Does BeiGene stock pay dividends?
No, BeiGene (BGNE) stock does not pay dividends to its shareholders as of January 02, 2025.
When is the next BeiGene dividend payment date?
BeiGene (BGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene?
BeiGene (BGNE) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.